Lv31
230 积分 2026-08-18 加入
PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
4天前
已完结
Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy
4天前
已关闭
The evolving landscape of drug targets
12天前
已关闭
Beyond the breakthrough for RAS-driven cancers
13天前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
24天前
已完结
Upcoming FDA approval decisions in Q4 2026
24天前
已关闭
From RAS inhibitor resistance to rational combination strategies
27天前
已完结
皖公网安备34019202002308
